Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): A randomised, open-label, phase 3 trial

The Lancet Oncology

Volumn 16, Issue 16, 2015, Pages 1630-1638

  Shukuya, Takehito ^a   Yamanaka, Takeharu ^b   Seto, Takashi ^c   Daga, Haruko ^d   Goto, Koichi ^e   Saka, Hideo ^f   Sugawara, Shunichi ^g   Takahashi, Toshiaki ^h   Yokota, Soichiro ⁱ   Kaneda, Hiroyasu ^j   Kawaguchi, Tomoya ^k   Nagase, Seisuke ^l   Oguri, Tetsuya ^m   Iwamoto, Yasuo ⁿ   Nishimura, Takashi ^o   Hattori, Yoshihiro ^p   Nakagawa, Kazuhiko ^j   Nakanishi, Yoichi ^q   Yamamoto, Nobuyuki ^r  

^a JUNTENDO UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY   (Japan)

^c NATIONAL KYUSHU CANCER CENTER   (Japan)

^d OSAKA CITY GENERAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f National Hospital Organisation Nagoya Medical Centre   (Japan)

^g SENDAI KOUSEI HOSPITAL   (Japan)

^h SHIZUOKA CANCER CENTER   (Japan)

ⁱ TONEYAMA NATIONAL HOSPITAL   (Japan)

^j KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l TOKYO MEDICAL UNIVERSITY   (Japan)

^m NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

ⁿ HIROSHIMA CITY HOSPITAL   (Japan)

^o KYOTO KATSURA HOSPITAL   (Japan)

^p HYOGO CANCER CENTER   (Japan)

^q KYUSHU UNIVERSITY   (Japan)

^r WAKAYAMA MEDICAL UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; NEDAPLATIN; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; TAXOID;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CANCER PAIN; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HICCUP; HUMAN; HYPERCALCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; INFECTIOUS COMPLICATION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SQUAMOUS CELL LUNG CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; VOMITING; YOUNG ADULT; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; JAPAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; JAPAN; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TAXOIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84951320694     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00305-8     Document Type: Article

References (29)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A Global cancer statistics, 2012. CA Cancer J Clin 2015, 65:87-108.
2. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012, 23(suppl 7):vii56-vii64.
3. NCCN clinical practice guidelines in oncology (NCCN guidelines) Version 5 National Comprehensive Cancer Network, (accessed Aug 25, 2015). http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
4. Guidelines for the treatment of lung cancer Japan Lung Cancer Society, (accessed Aug 25, 2015, in Japanese). https://www.haigan.gr.jp/modules/guideline/index.php?content_id=3.
5. Meza R, Meernik C, Jeon J, Cote ML Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. PLoS One 2015, 10:e0121323.
6. Sawabata N, Asamura H, Goya T, et al. Japanese Lung Cancer Registry study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol 2010, 5:1369-1375.
7. Thatcher N, Hirsch FR, Luft AV, et al. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 2015, 16:763-774. for the SQUIRE Investigators.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
9. Paz-Ares LG, de Marinis F, Dediu M, et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2013, 31:2895-2902.
10. Gao G, Ren S, Li A, et al. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: a meta-analysis from six phase III randomized controlled trials. Int J Cancer 2012, 131:E822-E829.
11. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014, 371:2167-2177.
12. Kubota K, Watanabe K, Kunitoh H, et al. Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004, 22:254-261.
13. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003, 21:3016-3024.
14. Yamamoto N, Tamura T, Kurata T, et al. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2009, 65:79-88.
15. Ota K, Wakui A, Majima H, et al. Phase I study of a new platinum complex 254-S, cis-diammine (glycolato)-platinum (II). Gan To Kagaku Ryoho 1992, 19:855-861.
16. Fukuda M, Shinkai T, Eguchi K, et al. Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 1990, 26:393-396.
17. Furuse K, Fukuoka M, Kurita Y, et al. A phase II clinical study of cis-diammine glycolato platinum, 254-S, for primary lung cancer. Gan To Kagaku Ryoho 1992, 19:879-884.
18. Naito Y, Kubota K, Ohmatsu H, et al. Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Ann Oncol 2011, 22:2471-2475.
19. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009, 27:1227-1234.
20. Efficacy guidelines: statistical principles for clinical trials The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, (accessed Aug 25, 2015). http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html.
21. Shimada M, Itamochi H, Kigawa J Nedaplatin: a cisplatin derivative in cancer chemotherapy. Cancer Manag Res 2013, 5:67-76.
22. Nakajima O, Inoue S, Kobayashi K Differences in intracellular uptake of cisplatin, carboplatin and 254-S among human lung cancer cell lines. Japan J Lung Cancer 1994, 34:313-319.
23. Jin J, Xu X, Wang F, et al. Second-line combination chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma. J Thorac Oncol 2009, 4:1017-1021.
24. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
25. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012, 30:2055-2062.
26. Gandara DR, Kawaguchi T, Crowley J, et al. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol 2009, 27:3540-3546.
27. Kenmotsu H, Tanigawara Y Pharmacokinetics, dynamics and toxicity of docetaxel: why the Japanese dose differs from the Western dose. Cancer Sci 2015, 106:497-504.
28. Ellis LM, Bernstein DS, Voest EE, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 2014, 32:1277-1280.
29. Garon EB, Ciuleanu T-E, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014, 384:665-673.